taniborbactam   Click here for help

GtoPdb Ligand ID: 10774

Synonyms: VNRX-5133 | VNRX5133
PDB Ligand
Compound class: Synthetic organic
Comment: Taniborbactam (VNRX-5133) is a clinical stage, injectable, broad-spectrum β-lactamase inhibitor [1,3]. It has activity against both serine- and metallo-β-lactamases (e.g. oxacillinase, Klebsiella pneumoniae carbapenemase, New Delhi metallo-beta-lactamase, Verona integron-encoded metallo-beta-lactamase and extended spectrum beta-lactamase) [4]. Taniborbactam will be administered alongside the cephalosporin antibacterial cefepime. It is being developed by Venatorx Pharmaceuticals in partnership with the Global Antibiotic Research & Development Partnership (GARDP).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 5
Rotatable bonds 8
Topological polar surface area 133.91
Molecular weight 389.21
XLogP 1.19
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES NCCNC1CCC(CC1)CC(=O)N[C@H]1Cc2cccc(c2OB1O)C(=O)O
Isomeric SMILES NCCNC1CCC(CC1)CC(=O)N[C@H]1Cc2cccc(c2OB1O)C(=O)O
InChI InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
InChI Key PFZUWUXKQPRWAL-PXCJXSSVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Taniborbactam is being investigated in combination with cefepime for the treatment of complicated urinary tract infections (cUTIs).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04951505 Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects Phase 1 Interventional Venatorx Pharmaceuticals, Inc.
NCT03690362 VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment Phase 1 Interventional Venatorx Pharmaceuticals, Inc. 2
NCT03840148 Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections (CERTAIN-1) Phase 3 Interventional VenatoRx Pharmaceuticals, Inc. The combination of cefepime + taniborbactam has a similar safety profile to that of meropenem and is superior for the treatment of cUTIs. 5-6